In in a recent meta-analysis, the estimated relative risks (RR) of enthesitis resolution in comparison to placebo across therapies were: RR = 1.99 (95% CI 1.36–2.90) for TNF inhibitors, RR = 2.31 (95% CI 1.60–3.34) for IL-17 inhibitors, RR = 1.41 (95% CI 1.02–1.95) for IL-12/23 inhibitors and RR = 0.85 (CI 0.74–0.99) for abatacept [103]. The gene discussed is IL17A; the disease is enthesitis.